Evidence mapPaperPMID 42440782Full record

ReviewMedComm2026

Cellular Senescence and Aging: Mechanisms, Disease Convergence, and Therapeutic Frontiers.

Guowei Cai, Jia Ren, Li Wang, Yingying Wu, Huirui Wang, Xiaomeng Cao, Hao Shang, Xuben Hou, Yujiu Wang, Haibo Xue and 1 more

Abstract readReview
In one paragraph

Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Guowei CaiClinical Drug Trials Institution Binzhou Medical University Hospital Binzhou China.
Jia RenState Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
Li WangRespiratory Medicine The Affiliated Hospital of Yan'an University Yan'an Shaanxi China.
Yingying WuCollege of Pharmaceutical Sciences Zhejiang University Hangzhou China.
Huirui WangDepartment of Natural Product Chemistry Key Laboratory of Chemical Biology (Ministry of Education) and State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine Shandong University Jinan Shandong China.
Xiaomeng CaoState Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
Hao ShangState Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
Xuben HouDepartment of Medicinal Chemistry State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds School of Pharmaceutical Sciences Cheeloo College of Medicine Shandong University Jinan Shandong China.
Yujiu WangClinical Drug Trials Institution Binzhou Medical University Hospital Binzhou China.
Haibo XueDepartment of Endocrinology and Metabolism Binzhou Medical University Hospital Binzhou China.
Ting DongClinical Drug Trials Institution Binzhou Medical University Hospital Binzhou China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellular senescence, a stress-induced, irreversible cell cycle arrest coupled with a proinflammatory secretory phenotype, has emerged as both a central driver of aging and a tractable therapeutic target. Although acute senescence contributes beneficially to tumor suppression and wound healing, chronic accumulation of senescent cells sustains systemic inflammaging and accelerates organ dysfunction. This review synthesizes current progress in aging biology into a unified mechanistic and translational framework. We first examine how primary aging hallmarks, such as genomic instability and epigenetic dysregulation, interact to trigger cellular senescence, then explore how these converging molecular processes give rise to distinct age-related pathologies across reproductive, pulmonary, hepatic, neurological, skeletal, and metabolic systems. We further evaluate emerging interventional strategies, from senolytics and senomorphics to rejuvenation approaches, while addressing key translational barriers including targeting specificity, senescence heterogeneity, and equitable access. By uniting mechanistic insight with disease-oriented and therapeutic perspectives, this review charts a strategic roadmap for deploying senescence-targeting therapies to extend human healthspan.

Indexed as

age‐associated diseasesaging hallmarksaging mechanismsantiaging strategiescellular senescence

Identifiers

PMID42440782
PMCPMC13334145

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.